Showing 4671-4680 of 5646 results for "".
- Nanoscope Therapeutics Announces Presentation at the 2020 AAOhttps://modernod.com/news/nanoscope-therapeutics-announces-presentation-at-the-2020-aao/2478545/Nanoscope Therapeutics, which is developing ocular gene therapy based on its proprietary ambient light activatable MCO Optogenetic Technology Platform, announced that an oral presentation at the Late Breaking Developments session of Retina Subspecialty Day will be made during the American Academy
- Lumenis Launches Digital Duet SLT-YAG Platformhttps://modernod.com/news/lumenis-launches-digital-duet-digital-slt-yag-platform/2478540/Lumenis announced the launch of the Digital Duet SLT-YAG platform. The Digital Duet, which Lumenis describes as the first digital SLT-YAG system on the market, improves glaucoma treatment and posterior capsulotomy with the introduction of advanced digital and connectivity capabilities—rede
- Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Material Recycled Through One By One Recycling Programhttps://modernod.com/news/bausch-lomb-reports-nearly-27-million-united-of-contact-lens-material-recycled-through-one-by-one-recycling-program/2478541/Bausch + Lomb announced that its exclusive ONE by ONE Recycling program has recycled nearly 27 million used contact lenses, top foils and blister packs since launching in November 2016. The program, made possible through a collaboration with TerraCycle, a leader in the collection and repurposing
- Zeiss Presents Integrated Workflow Advancements at AAOhttps://modernod.com/news/zeiss-presents-integrated-workflow-advancements-at-aao/2478534/The Medical Technology segment of Zeiss will present its latest integrated diagnostic and surgical advancements at the 2020 American Academy of Ophthalmology’s (AAO) Annual Meeting taking place virtually from Nov. 13-15. Zeiss will also be hosting multiple indu
- American Academy of Ophthalmology Leads Global Initiative to Address Worldwide Myopia Epidemichttps://modernod.com/news/american-academy-of-ophthalmology-leads-global-initiative-to-address-worldwide-myopia-epidemic/2478535/The number of Americans who are nearsighted has nearly doubled over the last 50 years to about 41.6 percent. This upward trend is evident in nearly every corner of the world, but nowhere near as dramatic as in East and Southeast Asia, where 80 to 90 percent of chi
- Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on DME at AAO 2020 Virtual Meetinghttps://modernod.com/news/kodiak-sciences-announces-presentation-of-ksi-301-phase-1b-clinical-study-data-focused-on-dme-at-aao-2020-virtual-meeting/2478532/Kodiak Sciences announced that a pre-recorded presentation of clinical study data on its investigational therapy KSI-301 is available at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Details of the presentation are as follows: Event: Late Breaking D
- New Data for Thyroid Eye Disease Treatment Tepezza to Be Presented at AAO Virtualhttps://modernod.com/news/new-data-for-thyroid-eye-disease-treatment-tepezza-to-be-presented-at-aao-virtual/2478527/Horizon Therapeutics announced new Tepezza (teprotumumab-trbw) data will be presented at the American Academy of Ophthalmology Annual Meeting, Nov. 13-15, 2020. Tepezza is the first and only medicine approved by the FDA for the treatment of Thyroid Eye Disease (TED) – a serious, progressive and v
- Samsung Bioepis Announces 1-year Results From Phase 3 Study of SB11 Proposed Lucentis Biosimilarhttps://modernod.com/news/samsung-bioepis-announces-1-year-results-from-phase-3-study-of-sb11-proposed-lucentis-biosimilar/2478526/Samsung Bioepis announced 1-year results from the phase 3 study on SB11, a proposed biosimilar to Lucentis (ranibizumab), in patients with neovascular age-related macular degeneration (AMD). This data will be presented for the first time at the American Academy of Ophthalmology (AAO) 2020 Virtual
- Gyroscope Therapeutics Announces First Patient Dosed in Phase 2 Trial Evaluating Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-announces-first-patient-dosed-in-phase-2-trial-evaluating-investigational-gene-therapy-for-dry-amd/2478523/Gyroscope Therapeutics announced the initiation of the phase 2 HORIZON trial evaluating GT005 in people with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The first patient to receive GT005 in HORIZON was enrolled and dosed in the United States by Jeff
- Leiters and EyeConnect International Announce Corporate Partnershiphttps://modernod.com/news/leiters-and-eyeconnect-international-announce-corporate-partnership/2478520/Leiters, a provider of ophthalmic compounded sterile preparations and pharmacy services, has entered into a partnership with EyeConnect International (ECI) in support of their newly created digital ophthalmic clinical networking platform. Terms of the deal were not disclosed. EyeCon